Form 8-K - Current report:
SEC Accession No. 0001420720-23-000017
Filing Date
2023-02-21
Accepted
2023-02-21 16:31:28
Documents
14
Period of Report
2023-02-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20230220x8k.htm   iXBRL 8-K 36582
2 EX-10.1 ibio-20230220xex10d1.htm EX-10.1 59542
  Complete submission text file 0001420720-23-000017.txt   228584

Data Files

Seq Description Document Type Size
3 EX-101.SCH ibio-20230220.xsd EX-101.SCH 4009
4 EX-101.DEF ibio-20230220_def.xml EX-101.DEF 3279
5 EX-101.LAB ibio-20230220_lab.xml EX-101.LAB 13578
6 EX-101.PRE ibio-20230220_pre.xml EX-101.PRE 10173
8 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20230220x8k_htm.xml XML 4623
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

IRS No.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 23648696
SIC: 2834 Pharmaceutical Preparations